Literature DB >> 18817998

A prospective study of patient adherence to topical treatments: 95% of patients underdose.

Andreas Storm1, Eva Benfeldt, Stig Ejdrup Andersen, Jørgen Serup.   

Abstract

BACKGROUND: Adherence is essential to a positive treatment outcome. Whether adequate doses of topically applied drugs are used among patients with dermatologic conditions has not been investigated adequately.
OBJECTIVES: The objective of this prospective study was to determine to what extent first-time outpatients with dermatologic conditions apply the appropriate dosage of initial treatment with topically administered medication.
METHODS: Consultations with first-time patients in the dermatologic outpatient clinic were observed. Patients receiving a prescription for a previously untried topically administered drug were eligible. The expected quantity of topical treatment to be used by each patient was calculated from the affected skin area to be treated. The affected area was estimated in numbers of palms of the hand, and an amount of 0.25 g of ointment or cream was chosen as sufficient treatment to cover the area of one palm. Two weeks after the consultation, a questionnaire with items regarding the size of the affected area, intentions to follow the treatment, and the applied dose the previous day was mailed to each patient. The questionnaires were personally collected from the patients' homes and at the same visit the patients' topical drug containers were weighed on a balance. Both patients and staff were blinded to the particular study purpose concerning adherence and dosing.
RESULTS: In all, 17 patients were eligible. The majority received a prescription for topical corticosteroids, and the median area to be treated was 3 palms of the hand (interquartile range: 1.5-8). Two patients did not redeem their prescriptions. Only one patient used the expected dosage; in general median 35% (interquartile range: 22%-50%) of the expected individual dosages were used. LIMITATIONS: Only first-time patients who received a new and previously untried topical treatment were included, resulting in a small study size.
CONCLUSIONS: Most first-time patients with dermatologic conditions underdose new topical treatments. Consequently, clinicians should always consider nonadherence when topical therapies fail.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817998     DOI: 10.1016/j.jaad.2008.07.039

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

Review 1.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

2.  [Not Available].

Authors:  Firas George Hougeir; Fran E Cook-Bolden; David Rodriguez; Joshua M Berlin
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

Review 3.  [Adequate prescription and application of topicals : How to calculate the right volume for the prescription of ointment needed?]

Authors:  D Homayoon; P Dahlhoff; M Augustin
Journal:  Hautarzt       Date:  2018-06       Impact factor: 0.751

4.  Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial.

Authors:  Annette Mollerup; Niels Kren Veien; Jeanne Duus Johansen
Journal:  BMC Dermatol       Date:  2012-06-12

5.  Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation.

Authors:  Giorgio L Colombo; Sergio Di Matteo; Giacomo Bruno; Giampiero Girolomoni; Gino Antonio Vena
Journal:  Clinicoecon Outcomes Res       Date:  2012-09-13

6.  A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).

Authors:  K A Papp; K Barber; R Bissonnette; M Bourcier; C W Lynde; Y Poulin; J Shelton; J Toole; A Vieira; M Poulin-Costello
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-07-01       Impact factor: 6.166

7.  Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

Authors:  K A Papp; K Barber; R Bissonnette; M Bourcier; C W Lynde; Y Poulin; J Shelton; K Garces; J Toole; M Poulin-Costello
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-21       Impact factor: 6.166

8.  Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.

Authors:  Steven Nisticò; Ester Del Duca; Valeria Torchia; Micaela Gliozzi; Ugo Bottoni; Carolina Muscoli
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

9.  Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).

Authors:  Kristian Reich; Ulrich Mrowietz; Eleni Karakasili; Ina Zschocke
Journal:  Arch Dermatol Res       Date:  2014-06-04       Impact factor: 3.017

10.  Knowledge, instruction and behavioural change: building a framework for effective eczema education in clinical practice.

Authors:  Deryn Lee Thompson; Murray John Thompson
Journal:  J Adv Nurs       Date:  2014-04-30       Impact factor: 3.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.